Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab-dttb
- Development stage
- Approved
- Lead developer
- Samsung Bioepis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Trastuzumab-dttb is a biosimilar monoclonal antibody to trastuzumab, marketed under the brand name Ontruzant. It is used for the treatment of HER2-overexpressing breast cancer (both early and metastatic) and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Trastuzumab-dttb binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2), inhibiting its signaling pathways, which leads to reduced proliferation and survival of cancer cells that overexpress this protein. The drug can be used alone or in combination with other chemotherapy agents depending on disease stage and prior treatments[1][4][3]. Its mechanism includes direct inhibition of tumor cell growth as well as immune-mediated effects such as antibody-dependent cell-mediated cytotoxicity[1][6].
- Brand names
- Ontruzant
- Other names
- trastuzumab-dttbTrastuzumab-biosimilar-Samsung BioepisAMT-901AMT901AMT 901
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab-dttb.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab-dttb.